OS THERAPIES INC (OSTX) Stock News

NYSEARCA:OSTX - US68764Y2072 - Common Stock

2.48 USD

+0.08 (+3.33%)

Last: 8/22/2025, 8:04:03 PM

2.42 USD

-0.06 (-2.42%)

After Hours: 8/22/2025, 8:04:03 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

OSTX Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: The Motley Fool

Os Therapies Posts Wider Loss in Q2

6 days ago - By: Benzinga

Earnings Outlook For OS Therapies

2 months ago - By: OS Therapies

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

2 months ago - By: OS Therapies

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference

2 months ago - By: OS Therapies

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

2 months ago - By: OS Therapies Inc.

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

3 months ago - By: OS Therapies Inc.

OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

3 months ago - By: OS Therapies Inc.

OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: OS Therapies

OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma

4 months ago - By: OS Therapies

OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040

4 months ago - By: OS Therapies

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

4 months ago - By: OS Therapies

OS Therapies FDA Meeting Request Granted

5 months ago - By: OS Therapies

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

5 months ago - By: OS Therapies

OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

5 months ago - By: OS Therapies

OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma

5 months ago - By: OS Therapies

OS Therapies to Host Analyst Day at NYSE on April 7, 2025

5 months ago - By: OS Therapies Inc.

OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update

5 months ago - By: OS Therapies

OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma

5 months ago - By: OS Therapies

OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers

5 months ago - By: OS Therapies

OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference

5 months ago - By: Benzinga - Mentions: IBO INTS EYEN PSTV ...

12 Health Care Stocks Moving In Thursday's After-Market Session

5 months ago - By: OS Therapies, Inc.

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference

6 months ago - By: OS Therapies, Inc.

OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

6 months ago - By: ACCESS Newswire - Mentions: CLDI

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

6 months ago - By: OS Therapies

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27

6 months ago - By: OS Therapies, Inc.

OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms

6 months ago - By: OS Therapies, Inc.

OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2